In a clinical phase 1b trial for advanced RCC patients, the combination of the VEGF receptor tyrosine kinase inhibitor Axitinib and the PD-1 monoclonal antibody Pembrolizumab yielded encouraging results. This evidence concerns the gene PDCD1 and renal cell carcinoma.